Keywords: b-ms, cuts, heart, disease, risk, factor, bristol-myers
B-MS cuts heart disease risk factor
Article | 22 March 2001
Bristol-Myers Squibb's Pravachol (pravastatin) has been shown toreduce levels of C-reactive protein, a risk factor for cardiovascular inflammation and heart ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
